MZE 782
Alternative Names: MZE-782Latest Information Update: 08 Oct 2024
At a glance
- Originator Maze Therapeutics
- Class Small molecules; Urologics
- Mechanism of Action SLC6A19 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Renal failure